Mark Leuchtenberger
Mr. Leuchtenberger has served as the chair of our Board of Directors since October 1, 2021. He is currently CEO of next generation vaccine developer SpyBiotech Ltd and recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO of Brooklyn ImmunoTherapeutics and Chairman, President and CEO of IRX Therapeutics. He has over 20 […]
Alon Ben-Noon
Mr. Ben-Noon is the Co-Founder and CEO of NeuroSense Therapeutics. Prior to the establishment of NeuroSense, Alon founded MediCan Consulting, a successful consultancy firm, with clients from diversified biotech companies, including Mediwound, Chiasma, Teva, Sol-Gel, FutuRx, NeuroDerm and others. MediCan excelled at executing efficient, accurate, and innovative drug development programs for its clients. Mr. Ben-Noon […]
Christine Pellizzari
Ms. Pellizzari has served as the Chief Legal Officer of Science 37 since July 2021. Prior to joining Science 37, Ms. Pellizzari served as the General Counsel and Corporate Secretary of Insmed, Inc., a public biotech company focused on serious and rare diseases, from 2013 to 2018 and as Chief Legal Officer from 2018 to […]
Cary Claiborne
Cary J. Claiborne, MBA, is the founder and CEO of Prosperity Capital Management, LLC, a Private Investment and Advisory firm. His career spans over 35 years in the Finance, Pharma and Biotech industries. Mr. Claiborne previously served as the Chief Financial Officer and member of the Board of Directors at Indivior PLC (INDV, FTSE 500), […]
Dr. Revital Mandil-Levin
Dr. Mandil-Levin has more than 15 years’ experience in biotech startups and product development in the pharmaceutical industry. She is currently the CEO and founder of Nanocarry Therapeutics Ltd., a private company developing a proprietary platform technology for the delivery of biologics across the blood-brain barrier for CNS indications. From September 2019 to November 2020, […]
Roy Golan
Mr. Roy Golan has over 20 years of experience in the Biotech and the Pharmaceuticals industries, across a range of roles and companies. Up to June 2024, Mr. Golan served as the CFO of Ayala Pharmaceuticals Inc. (OTCQX: ADXS), a clinical-stage oncology company, following its merger with BioSight Ltd., a private pharmaceutical company developing innovative […]
